Declarations
Funding: No funding has been obtained for the meta-trial. Individual contributing studies/countries are responsible for their own funding.
Availability of data and material: The datasets used for the current manuscript are available from the corresponding author on reasonable request.
Competing interests:
AA and MCR report a research grant for preclinical research from Grifols and from Fisher&Paykel, and payment as Scientific Advisor for Grifols, outside the submitted work. JL reports receiving an Academic Collaboration grant funded by Science Foundation Ireland and Aerogen Inc. for a different study (CHARTER-Ireland). JS is Scientific Advisor for and has shares in Ockham Biotech Ltd, which holds patents around the use of inhaled heparin. TW is Chief Investigator of the ACCORD COVID Research Programme. DS reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees from Glenmark, personal fees from Gossamerbio, personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal fees from Theravance, personal fees from Verona, outside the submitted work. All other authors have nothing to disclose.
Acknowledgements: The authors wish to acknowledge Ms Beth Croce, medical illustrator, for designing the figure for this manuscript.
Keywords: COVID-19, ARDS, SARS, inhaled heparin, nebulised heparin, unfractionated heparin, SARS-CoV-2, respiratory failure, pandemic, randomised controlled trial, meta-trial
Meta-trial registration: ClinicalTrials.gov ID NCT04635241